^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | PHI-501 (pan-RAF inhibitor, DDR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5495 - PHI-501, a potent and novel inhibitor of NRAS mutated acute myeloid leukemia
Published date:
03/09/2022
Excerpt:
These results show the significant ability of PHI-501 to inhibit the progression of NRAS activated AML tumor growth, making it a strong candidate for the treatment of AML. The preclinical evaluation of PHI-501, a novel N-RAS inhibitor, showed clear evidence of anticancer activity for AML and improved efficacy in both in vitro and in vivo models.
